Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12

Br J Haematol. 2003 Feb;120(4):695-8. doi: 10.1046/j.1365-2141.2003.04133.x.

Abstract

Microvessel density (MVD), a surrogate marker for angiogenesis, was evaluated by anti-CD34 and CD105 monoclonal antibodies (Abs), and found to be increased in the bone marrow (BM) of hairy cell leukaemia (HCL) patients and in a preclinical model of non-obese diabetic/severe combined immunodeficient mice transplanted with the HCL line Bonna-12. The anti-CD105 Ab was significantly more sensitive than anti-CD34 Ab in identifying blood vessels. The BM tumour burden significantly decreased in patients treated with interferon-alpha, but the mean value of MVD remained unchanged. These data suggest that angiogenesis may be involved in the pathogenesis of HCL.

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow / blood supply*
  • Female
  • Humans
  • Interferon-alpha / therapeutic use
  • Leukemia, Hairy Cell / drug therapy
  • Leukemia, Hairy Cell / pathology*
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Microcirculation
  • Middle Aged
  • Neoplasm Transplantation
  • Neovascularization, Pathologic / pathology*
  • Tumor Cells, Cultured

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Interferon-alpha